Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. uri icon

authors

  • Anna Oh, PhD, MPH, RN
  • Tran, Dang M
  • McDowell, Leann C
  • Keyvani, Dor
  • Barcelon, Jay Andrew
  • Merino, Oscar
  • Wilson, Leslie

publication date

  • January 2017